Initiation of lenacapavir with dose escalation in a patient receiving rifabutin: A case report with therapeutic drug monitoring
Lenacapavir is a first‐in‐class HIV‐1 capsid inhibitor with long‐acting pharmacokinetics that enable 6‐monthly subcutaneous dosing after initiation with oral lead‐in. Lenacapavir is a CYP3A4, UGT1A1 and P‐gp substrate; inducers of these enzymes and P‐gp can significantly decrease lenacapavir concentrations. In patients receiving lenacapavir for HIV pre‐exposure prophylaxis (PrEP), supplemental lenacapavir doses can be administered if rifabutin (moderate inducer) or rifampin (potent inducer) are initiated. However, these recommendations have not been extended to lenacapavir when used for HIV treatment, and little is known about initiating lenacapavir in patients on stable therapy with inducers. We describe a 30‐year‐old man with advanced HIV infection and disseminated Mycobacterium avium complex infection receiving rifabutin and concurrent darunavir/ritonavir in whom lenacapavir was initiated with a 50% increase in both oral (900 mg on Days 1 and 2) and subcutaneous loading doses (1390.5 mg on Day 1). Therapeutic drug monitoring using validated UPLC–MS/MS method demonstrated that lenacapavir plasma concentrations remained above the target of 15.5 ng/mL (4× protein‐adjusted 95% effective concentration [PA‐EC 95 ]) over the dosing interval, with C max of 245.7 ng/mL and a projected C min of 19.5 ng/mL at 6 months. HIV viral load remained suppressed. This case demonstrates that dose‐adjusted lenacapavir can achieve therapeutic exposures in the presence of pre‐existing moderate induction. These findings provide clinically relevant pharmacological insight to support the use of lenacapavir in complex patients requiring rifamycin therapy.
Authors
- Amanda K. Hempel (ORCID: https://orcid.org/0000-0002-3586-746X)
- Catia Marzolini (ORCID: https://orcid.org/0000-0002-2312-7050)
- Aaron S. Devanathan (ORCID: https://orcid.org/0000-0002-2778-3725)
- Alexandra Cheung
- Alice Lin-In Tseng (ORCID: https://orcid.org/0000-0002-6480-6690)
- Felix Leung (ORCID: https://orcid.org/0000-0001-8166-3794)
- Mark T. McIntyre (ORCID: https://orcid.org/0000-0001-9705-1354)
Institutions
- Mount Sinai Hospital (CA)
- University Health Network (CA)
- University of Liverpool (GB)
- University of Pittsburgh (US)
- University of Toronto (CA)
- Centre Hospitalier Universitaire Vaudois (CH)
- Sinai Health System (CA)
- University of Lausanne (CH)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1002/bcp.70932
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00